Youcare Pharmaceutical Advances Dual mRNA Vaccine Pipeline with NMPA Approvals for RSV and Herpes Zoster Candidates
Youcare Pharmaceutical Group (SHA: 688658) announced separate clinical trial approvals from China’s National Medical Products...
Youcare Pharmaceutical
Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Youcare Pharmaceutical Group (SHA: 688658) announced that its YKYY018 aerosolized inhalation formulation has received approval...
APC Group and Youcare Pharmaceutical Forge Strategic Partnership – Global Distribution Alliance Targets China-India Pharma Collaboratio
APC Group and Youcare Pharmaceutical Group (SHA: 688658) signed a strategic cooperation framework agreement establishing...
Youcare Pharma Secures FDA Approval for YKYY013, a Novel siRNA Therapy for Chronic Hepatitis B
Youcare Pharmaceutical Group (SHA: 688658) announced that the U.S. Food and Drug Administration (FDA) has...
Youcare Pharma’s YKYY029 Receives FDA IND Approval for Hypertension Treatment
China-based Youcare Pharmaceutical Group (SHA: 688658) announced on July 24, 2025, that its subsidiary, Beijing...
Youcare Pharma Subsidiary Gains NMPA Clearance for Phase I Study of siRNA Hypertension Drug YKYY029
China-based Youcare Pharma (SHA: 688658) announced that its subsidiary Youcare InnoTech and partner Hangzhou Tianlong...
Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received clinical clearance from...
Youcare Pharmaceutical Group Gets NMPA Approval for YKYY015 Phase I Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has announced that it has received approval from the...
Youcare Pharmaceutical Partners with Sinopharm Heilongjiang to Broaden Market Presence
Youcare Pharmaceutical Group (SHA: 688658), a China-based pharmaceutical company, has entered into a partnership with...
Youcare Pharmaceutical’s YKYYO17 Receives Ethical Approval for COVID-19 Treatment Study
China-based Youcare Pharmaceutical Group (SHA: 688658) has received ethical approval from the China-Japan Friendship Hospital...
Youcare’s YKYYO17 Aerosol Inhalation Agent Approved for COVID-19 Clinical Study
China-based Youcare Pharmaceutical Group’s YKYYO17 aerosol inhalation agent, a broad-spectrum coronavirus membrane fusion inhibitor polypeptide...